Sign in Create account

Sun Pharmaceutical Industries Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: SUNPHARMA BSE: 524715
₹1816.60
▼ -48.40 (-2.60%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
72/100
Strong
Valuation
8/100
Expensive
Momentum
30/100
Bearish

QVM read Quality, pricey and fading Quality Strong, Valuation Expensive, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹435,863 Cr
PE (TTM)
146.5
Industry median 36.1 (152 companies)
Price to Book
5.2
PEG (TTM)
-3.9
Institutions holding %
36.71%
FII + DII, latest filed period
Piotroski Score
5
Relative return vs Nifty50, qtr %
2.5
Relative return vs Sector, qtr %
-2.7
Free Cash Flow
₹8,810 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
48.39%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-37.61%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-13.30%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
47.99%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
2.48%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
2.82
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.05
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
5.15
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
19.42%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
30.74%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
24.36%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
10.58%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
17.94%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
13.72%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • Yes Debt to equity is below 0.5 (0.05)
  • No Return on equity is 15% or more (13.7%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (1.6% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

0 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.6%
Low 1814.2000 · High 1863.6000
1W return
-2.6%
Low 1814.2000 · High 1880.0000
1M return
-8.5%
Low 1814.2000 · High 1963.1000
52W return
11.0%
Low 1583.7000 · High 2046.9000
Lifetime High ₹2673.8000 (Feb. 22, 2000)
Lifetime Low ₹198.0000 (Nov. 25, 1996)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish1
Bearish5
5D
1841.6
10D
1849.5
20D
1864.0
50D
1883.3
100D
1868.6
200D
1807.6

Delivery and volume

Day avg. delivery
64.3%
Week avg. delivery
63.9%
Month avg. delivery
64.5%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1831.47
Pivot
First resistance1848.73
Second resistance1880.87
Third resistance1898.13
First support1799.33
Second support1782.07
Third support1749.93
Day RSI38.9
Day MFI40.3
Day MACD-18.68
Day MACD signal-17.70

Beta

1M0.57
3M0.36
1Y0.47
3Y0.53

Price change analysis

↓ -8.5%
Over 1 Month
LowHigh
1814.201963.10
↓ -2.7%
Over 3 Months
LowHigh
1814.202046.90
↑ 5.1%
Over 6 Months
LowHigh
1613.602046.90
↑ 11.0%
Over 1 Year
LowHigh
1583.702046.90
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 146.5 (own history: 84.2–172.0)
Sell Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹5,741 Cr
Net profit (June 30, 2026)
₹1,115 Cr
Basic EPS (June 30, 2026)
₹4.6000

Ranks #1 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter54.48%
  • Mutual funds12.84%
  • FII/FPI14.53%
  • Other DII9.34%
  • Public8.81%

Largest holders

NameCategoryShares %Shares
Shanghvi Finance Private LimitedPromoter40.3000%967051732
Dilip.S.ShanghviPromoter9.6000%230385155
Life Insurance Corporation Of IndiaPublic5.5300%132770818
Icici Prudential Value FundPublic3.7200%89198583
Sbi Nifty 50 EtfPublic2.3600%56689578

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 54.48% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 15.93% to 14.53% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 11.96% to 12.84% in Jun 2026 qtr

197 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 1103 insider trades, 9 SAST, 649 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
30 Aug 2023 RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) Promoter group Pledge 0 ₹225.63 Cr
23 May 2023 RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) Promoter group Pledge 0 ₹93.75 Cr
29 Mar 2023 ADITYA MEDISALES LIMITED Promoter group Pledge Revoke 0 ₹589.39 Cr
22 Mar 2023 RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) Immediate relative Pledge 0 ₹158.60 Cr
20 Mar 2023 Sailesh T. Desai Director Sell 0 ₹0
9 Mar 2023 Shanghvi Finance Private Limied Promoter group Pledge Revoke 0 ₹11.57 Cr
6 Mar 2023 RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) Immediate relative Pledge Revoke 0 ₹777.13 Cr
6 Mar 2023 RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) Immediate relative Pledge 0 ₹112.16 Cr
23 Feb 2023 RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) Immediate relative Pledge 0 ₹115.26 Cr
23 Feb 2023 RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) Immediate relative Pledge 0 ₹234.39 Cr

All insider and SAST disclosures →

Deals (Bulk & Block)

All 118 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
24 Jun 2026 THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MUTB400045794 Block Buy 154,424 1868.0000 NSE
24 Jun 2026 THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828 Block Sell 154,424 1868.0000 NSE
9 Oct 2025 GOLDMAN SACHS BANK EUROPE SE - ODI Block Buy 148,233 1631.6000 NSE
9 Oct 2025 GOLDMAN SACHS (SINGAPORE) PTE - ODI Block Sell 148,233 1631.6000 NSE
27 Feb 2024 JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITED Block Sell 656,286 1556.9500 BSE
27 Feb 2024 THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT Block Buy 656,286 1556.9500 BSE
25 Jan 2024 SOCIETE GENERALE Block Buy 3,253,896 1382.1000 BSE
25 Jan 2024 BNP PARIBAS ARBITRAGE Block Sell 3,253,896 1382.1000 BSE
25 Oct 2022 ISHARES CORE MSCI EMERGING MARKETS ETF Block Buy 755,497 987.0000 NSE
25 Oct 2022 ISHARES CORE EMERGING MARKETS MAURITIUS CO Block Sell 755,497 987.0000 NSE

All bulk and block deals →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
31 Jul 2026 Financial Results Yes
22 May 2026 Financial Results/Dividend Yes
31 Jan 2026 Financial Results/Dividend Yes
5 Nov 2025 Financial Results Yes
31 Jul 2025 Financial Results Yes

Corporate Announcements

All 10 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
2 Oct 2026 Company Update Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Oct 2026 AGM/EGM Sun Pharmaceutical Industries Ltd - 524715 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
1 Oct 2026 Company Update Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
30 Sep 2026 Company Update Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Newspaper Publication
29 Sep 2026 Company Update Sun Pharmaceutical Industries Ltd - 524715 - ESG Overview For FY 2025-26
28 Sep 2026 Company Update Sun Pharmaceutical Industries Ltd - 524715 - Completion And Result Of Postal Ballot Dated 25 August 2026
28 Sep 2026 Company Update Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
25 Sep 2026 Insider Trading / SAST Sun Pharmaceutical Industries Ltd - 524715 - Closure of Trading Window
11 Sep 2026 Company Update Sun Pharmaceutical Industries Ltd - 524715 - Intimation Under Regulation 30 Of SEBI LODR
9 Sep 2026 Company Update Sun Pharmaceutical Industries Ltd - 524715 - Incorporation Of A Subsidiary Company

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.05)
  • Healthy liquidity (Current Ratio 2.82)

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

  • PE above 35 (146.5) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.

Part of: NIFTY 100, NIFTY 100, NIFTY 200, NIFTY 200, NIFTY 50, NIFTY 50, NIFTY 500, NIFTY 500, NIFTY PHARMA, NIFTY PHARMA

Frequently asked questions about Sun Pharmaceutical Industries Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.